Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4753 - Pathogens and characteristics of candidemia in hospitals of Rostov-on-Don. Multicenter study in Russia

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Olga Kutsevalova

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

O.Y. Kutsevalova1, O.I. Kit2, N.I. Panova1, I.B. Lysenko3, V.V. Dmitrieva1, D.A. Rozenko4, E.A. Kalabanova5, I.S. Mitashok5, G. Klyasova6, Y.V. Shatokhin7, I.V. Snezhko7, D.V. Martynov7, V.N. Malygin7, O.V. Korosteleva8, A.A. Matsuga8, K.S. Aslanyan9, L.Y. Vladimirova5

Author affiliations

  • 1 Laboratory Of Microbiology, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 2 Department Of Surgical oncology, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 3 Department Of Hematology, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 4 Department Of Anesthesiology And Reanimation, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 5 Medical Department, Rostov Research Institute of Oncology, 344037 - Rostov-on-Don/RU
  • 6 Hematology, National Research Center for Hematology, Moscow/RU
  • 7 Department, Rostov State Medical University, 344037 - Rostov-on-Don/RU
  • 8 Department, Hospital, 344037 - Rostov-on-Don/RU
  • 9 Department, Rostov Regional Children's Hospital, 344037 - Rostov-on-Don/RU
More

Resources

Abstract 4753

Background

Invasive candidiasis is a serious nosocomial infection developing generally in patients at risk; it is characterized by a severe clinical course and high (10-49%) additive mortality. It develops predominantly in immunocompromised, especially cancer, patients and patients in intensive care units. The purpose of the study was to analyze the etiology of invasive candidiasis and in vitro activity of caspofungin and azoles for isolates of Candida fungi.

Methods

Isolates were obtained in hospital departments in Rostov-on-Don and Rostov region in 2013-2016. Candida fungi were identified using MALDI-TOF MS; interpretation was performed according to CLSI 2012, M27-S4 criteria. Sensitivity testing was performed using the Sensititre system (Trek Diagnostic Systems, England).

Results

92 Candida isolates were obtained from blood culture: C. albicans - 31.5% (29) and non-albicans - 68.5% (63), including C. tropicalis 30.2% (19), C. parapsilosis 28.6% (18), C. glabrata 19.0% (12), C. krusei 15.9% (10) and C. guilliermondii 6.3% (4). Fungal-bacterial associations were found in 5 cases; such combinations worsened the patient’s condition and complicated the treatment. The table demonstrates comparative activities of caspofungin, fluconasole and voriconasole (susceptible – S, intermediate – I, resistant – R) in % to Candida spp.Table: 1785P

SpeciesnCaspofungin S/ I/ R (%)Fluconazole S/ I/ R (%)Voriconazole S/ I/ R (%)
C. albicans29100/ 0/ 082/ 3/ 1590/ 6/ 4
C. parapsilosis1898/ 0/ 282/ 4/ 1488/ 11/ 1
C. tropicalis19100/ 0/ 090/ 5/ 5100/ 0/ 0
C. glabrata1295/ 5/ 086/ 9/ 5N/A
C. krusei1083/ 4/ 13N/A100/ 0/ 0

Conclusions

Candida non albicans prevailed among invasive candidiasis pathogens (68.5%), which could be associated with the use of azole antifungal agents for the prophylaxis and empirical therapy. Dominating isolates showed decreased activity to caspofungin and azoles. Acquired resistance to azoles was noted for C. parapsilosis and C. albicans. Special attention should be paid to C. glabrata characterized by high lethality and high resistance rates. The results demonstrate the advisability of microbiological monitoring of invasive candidiasis pathogens.

Clinical trial identification

Legal entity responsible for the study

Ministry of Health of the Russian Federation.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.